Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine : a pooled analysis of four randomised trials

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-out in the UK will involve vaccinating...

ver descrição completa

Detalhes bibliográficos
Autor principal: Voysey, Merryn (author)
Outros Autores: Sprinz, Eduardo (author), Stein, Ricardo (author), Cunha, Debora Rosilei Miquini de Freitas (author), Silva, Larissa Pozzebon da (author), Santos, Thainá Garbino dos (author), Dias, Ana Luiza Perez Olive (author), Pinheiro, Jéssica Morgana Gediel (author), Sorio, Guilherme Geraldo Lovato (author), Vieira, Taiane Alves (author), Zambrano, Marina Bauer (author), Zimmer, Rafael Leal (author), Arns, Beatriz (author), Oxford COVID Vaccine Trial Group (author)
Formato: other article
Idioma:eng
Publicado em: 2021
Assuntos:
Infecções por coronavirus
COVID-19
SARS-CoV-2
Vacinas
Texto completo:http://hdl.handle.net/10183/230689
País:Brasil
Oai:oai:www.lume.ufrgs.br:10183/230689

Texto Completo

http://hdl.handle.net/10183/230689

Registos relacionados